Please provide your email address to receive an email when new articles are posted on . Cal/BDP is a combination formula, comprised of calcipotriol and betamethasone dipropionate, that treats ...

Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that the United States Patent Office has granted U.S.

Arcutis Biotherapeutics has delivered a phase 3 win for its roflumilast foam formulation. With the cream version already under review at the FDA in plaque psoriasis, the topical drug delivery ...

The foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast has been approved by the US Food and Drug Administration (FDA) for treating plaque psoriasis of the scalp and body in ...

The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...

The regulatory submission in the US is based on studies of patients with plaque psoriasis. These include the Phase 3a PSO-FAST study which evaluated efficacy and safety at four weeks [1] and the Phase ...

The first commercial product developed for the American market by Israeli biotech start-up Foamix has received FDA approval, the company announced last week. Finacea Foam, a 15% solution of azelaic ...

NEW YORK (Reuters Health) - A foam formulation of the popular hair re-growth aid Rogaine is an effective treatment for hair loss in men and may be safer and easier to apply than the original liquid ...

Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that the United States Patent Office has granted U.S.